ViroCell Biologics News and Resources

ViroCell Biologics, a specialist viral vector CDMO for cell and gene therapy clinical trials, is supporting a newly launched clinical study at University College London (UCL). The trial, known as CARPALL (cohort 4), is investigating a next-generation CAR T-cell therapy

ViroCell Biologics has successfully completed an oversubscribed convertible note offering, aimed at driving the company’s growth in the cell and gene therapy (CGT) sector. The funding round was led by new investor First Light Asset Management LLC, with participation from

ViroCell Biologics, a cell and gene therapy contract development and manufacturing organization (CDMO), has entered into a five-year Master Services Agreement (MSA) with a prominent U.S. NCI-designated cancer center. This agreement will enable the cancer center to utilize ViroCell’s comprehensive